Switch to:
Also traded in: UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.92
ICLR's Cash-to-Debt is ranked lower than
71% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ICLR: 0.92 )
Ranked among companies with meaningful Cash-to-Debt only.
ICLR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.55  Med: 22.59 Max: No Debt
Current: 0.92
Equity-to-Asset 0.51
ICLR's Equity-to-Asset is ranked lower than
60% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ICLR: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
ICLR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.64 Max: 0.77
Current: 0.51
0.44
0.77
Interest Coverage 24.78
ICLR's Interest Coverage is ranked lower than
61% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. ICLR: 24.78 )
Ranked among companies with meaningful Interest Coverage only.
ICLR' s Interest Coverage Range Over the Past 10 Years
Min: 17.93  Med: 42.14 Max: 257.77
Current: 24.78
17.93
257.77
Piotroski F-Score: 6
Altman Z-Score: 5.37
Beneish M-Score: -2.71
WACC vs ROIC
3.50%
27.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.93
ICLR's Operating Margin % is ranked higher than
88% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ICLR: 18.93 )
Ranked among companies with meaningful Operating Margin % only.
ICLR' s Operating Margin % Range Over the Past 10 Years
Min: 3.11  Med: 11.24 Max: 18.93
Current: 18.93
3.11
18.93
Net Margin % 15.94
ICLR's Net Margin % is ranked higher than
91% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ICLR: 15.94 )
Ranked among companies with meaningful Net Margin % only.
ICLR' s Net Margin % Range Over the Past 10 Years
Min: 2.42  Med: 9.35 Max: 15.94
Current: 15.94
2.42
15.94
ROE % 29.19
ICLR's ROE % is ranked higher than
91% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ICLR: 29.19 )
Ranked among companies with meaningful ROE % only.
ICLR' s ROE % Range Over the Past 10 Years
Min: 3.39  Med: 17.27 Max: 30.7
Current: 29.19
3.39
30.7
ROA % 14.82
ICLR's ROA % is ranked higher than
90% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ICLR: 14.82 )
Ranked among companies with meaningful ROA % only.
ICLR' s ROA % Range Over the Past 10 Years
Min: 2.31  Med: 9.79 Max: 14.82
Current: 14.82
2.31
14.82
ROC (Joel Greenblatt) % 96.51
ICLR's ROC (Joel Greenblatt) % is ranked higher than
91% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ICLR: 96.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ICLR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.45  Med: 41.07 Max: 121.76
Current: 96.51
12.45
121.76
3-Year Revenue Growth Rate 11.20
ICLR's 3-Year Revenue Growth Rate is ranked higher than
70% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ICLR: 11.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ICLR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.6  Med: 11.75 Max: 54.3
Current: 11.2
-14.6
54.3
3-Year EBITDA Growth Rate 34.60
ICLR's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ICLR: 34.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ICLR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.1 Max: 52.9
Current: 34.6
0
52.9
3-Year EPS without NRI Growth Rate 41.30
ICLR's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ICLR: 41.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ICLR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34.2  Med: 8.15 Max: 94.7
Current: 41.3
-34.2
94.7
GuruFocus has detected 3 Warning Signs with Icon PLC $ICLR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ICLR's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ICLR Guru Trades in Q2 2016

Steven Cohen 166,900 sh (New)
Jeremy Grantham 26,300 sh (+224.69%)
Jim Simons 153,400 sh (+133.49%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 931,328 sh (-0.07%)
» More
Q3 2016

ICLR Guru Trades in Q3 2016

Scott Black 29,492 sh (New)
Jeremy Grantham 44,200 sh (+68.06%)
Jim Simons 212,200 sh (+38.33%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 928,453 sh (-0.31%)
Steven Cohen 161,200 sh (-3.42%)
» More
Q4 2016

ICLR Guru Trades in Q4 2016

Jim Simons 271,100 sh (+27.76%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 879,550 sh (-5.27%)
Steven Cohen 138,500 sh (-14.08%)
Scott Black 20,584 sh (-30.20%)
Jeremy Grantham 3,129 sh (-92.92%)
» More
Q1 2017

ICLR Guru Trades in Q1 2017

Jim Simons 955,860 sh (+252.59%)
Steven Cohen 369,500 sh (+166.79%)
Chuck Royce 143,700 sh (unchged)
Scott Black Sold Out
Jeremy Grantham Sold Out
Ron Baron 829,200 sh (-5.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711 
Compare:NAS:PRAH, OTCPK:CZMWY, NAS:VWR, NYSE:CRL, NAS:BRKR, OTCPK:SWTUY, NYSE:ALR, NAS:PRXL, NAS:DXCM, NAS:EXAS, NAS:INCR, NYSE:BIO, NYSE:PKI, NAS:NEOG, NAS:QGEN, OTCPK:BMXMF, NAS:AXDX, NAS:MYGN, NAS:FMI, NAS:VREX » details
Traded in other countries:0NBW.UK,
Headquarter Location:Ireland
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries.

Icon is a global contract research organization that provides drug development and clinical testing services to pharmaceutical, biotechnology, and medical device companies. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities.

Top Ranked Articles about Icon PLC

Scott Black’s Top 4 New Holdings of 3rd Quarter Guru’s largest purchase is research and development company
Scott Black (Trades, Portfolio), president and founder of Delphi Management, acquired nine new holdings in the third quarter. His top four new positions are Icon PLC (NASDAQ:ICLR), Lionbridge Technologies (NASDAQ:LIOX), Omega Healthcare Investors (NYSE:OHI) and National General Holdings Corp. (NASDAQ:NGHC). Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.77
ICLR's PE Ratio is ranked higher than
81% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. ICLR: 18.77 )
Ranked among companies with meaningful PE Ratio only.
ICLR' s PE Ratio Range Over the Past 10 Years
Min: 9.92  Med: 18.08 Max: 80.63
Current: 18.77
9.92
80.63
Forward PE Ratio 17.42
ICLR's Forward PE Ratio is ranked higher than
96% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. ICLR: 17.42 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.77
ICLR's PE Ratio without NRI is ranked higher than
81% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. ICLR: 18.77 )
Ranked among companies with meaningful PE Ratio without NRI only.
ICLR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.92  Med: 17.97 Max: 80.63
Current: 18.77
9.92
80.63
Price-to-Owner-Earnings 17.41
ICLR's Price-to-Owner-Earnings is ranked higher than
59% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. ICLR: 17.41 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ICLR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.23  Med: 24.56 Max: 437.5
Current: 17.41
6.23
437.5
PB Ratio 5.14
ICLR's PB Ratio is ranked lower than
60% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ICLR: 5.14 )
Ranked among companies with meaningful PB Ratio only.
ICLR' s PB Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.55 Max: 5.6
Current: 5.14
1.34
5.6
PS Ratio 3.01
ICLR's PS Ratio is ranked higher than
60% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ICLR: 3.01 )
Ranked among companies with meaningful PS Ratio only.
ICLR' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.59 Max: 3.3
Current: 3.01
0.87
3.3
Price-to-Free-Cash-Flow 16.03
ICLR's Price-to-Free-Cash-Flow is ranked higher than
56% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. ICLR: 16.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ICLR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.85  Med: 20.58 Max: 533.56
Current: 16.03
5.85
533.56
Price-to-Operating-Cash-Flow 14.09
ICLR's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. ICLR: 14.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ICLR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.07  Med: 15.94 Max: 86.1
Current: 14.09
5.07
86.1
EV-to-EBIT 15.15
ICLR's EV-to-EBIT is ranked higher than
97% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ICLR: 15.15 )
Ranked among companies with meaningful EV-to-EBIT only.
ICLR' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.5  Med: 15 Max: 48
Current: 15.15
6.5
48
EV-to-EBITDA 12.85
ICLR's EV-to-EBITDA is ranked higher than
97% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ICLR: 12.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICLR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 12 Max: 23.6
Current: 12.85
4.9
23.6
PEG Ratio 0.43
ICLR's PEG Ratio is ranked higher than
98% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. ICLR: 0.43 )
Ranked among companies with meaningful PEG Ratio only.
ICLR' s PEG Ratio Range Over the Past 10 Years
Min: 0.34  Med: 1.46 Max: 8.54
Current: 0.43
0.34
8.54
Shiller PE Ratio 39.55
ICLR's Shiller PE Ratio is ranked higher than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. ICLR: 39.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
ICLR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.01  Med: 23.65 Max: 48.99
Current: 39.55
10.01
48.99
Current Ratio 1.91
ICLR's Current Ratio is ranked lower than
63% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ICLR: 1.91 )
Ranked among companies with meaningful Current Ratio only.
ICLR' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.91
1.12
3.61
Quick Ratio 1.91
ICLR's Quick Ratio is ranked lower than
56% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ICLR: 1.91 )
Ranked among companies with meaningful Quick Ratio only.
ICLR' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.91
1.12
3.61
Days Sales Outstanding 73.21
ICLR's Days Sales Outstanding is ranked lower than
73% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ICLR: 73.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICLR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.88  Med: 89.44 Max: 94.82
Current: 73.21
66.88
94.82
Days Payable 104.06
ICLR's Days Payable is ranked higher than
78% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ICLR: 104.06 )
Ranked among companies with meaningful Days Payable only.
ICLR' s Days Payable Range Over the Past 10 Years
Min: 1.98  Med: 11.29 Max: 130.79
Current: 104.06
1.98
130.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 4.00
ICLR's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ICLR: 4.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICLR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.5  Med: -1.45 Max: 16.4
Current: 4
-61.5
16.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 67.77
ICLR's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ICLR: 67.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ICLR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.88  Med: 7.07 Max: 67.77
Current: 67.77
0.88
67.77
Price-to-Tangible-Book 17.75
ICLR's Price-to-Tangible-Book is ranked lower than
87% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ICLR: 17.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ICLR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.64  Med: 3.51 Max: 39.34
Current: 17.75
0.64
39.34
Price-to-Intrinsic-Value-Projected-FCF 1.54
ICLR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
61% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ICLR: 1.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ICLR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.71 Max: 6.7
Current: 1.54
0.51
6.7
Price-to-Median-PS-Value 1.88
ICLR's Price-to-Median-PS-Value is ranked lower than
85% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ICLR: 1.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ICLR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.92 Max: 1.88
Current: 1.88
0.36
1.88
Price-to-Peter-Lynch-Fair-Value 0.75
ICLR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
96% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. ICLR: 0.75 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ICLR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.17 Max: 3.26
Current: 0.75
0.2
3.26
Price-to-Graham-Number 3.83
ICLR's Price-to-Graham-Number is ranked lower than
56% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. ICLR: 3.83 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ICLR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.42  Med: 1.67 Max: 5.83
Current: 3.83
0.42
5.83
Earnings Yield (Greenblatt) % 6.61
ICLR's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ICLR: 6.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ICLR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.1  Med: 6.65 Max: 15.4
Current: 6.61
2.1
15.4
Forward Rate of Return (Yacktman) % 47.50
ICLR's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. ICLR: 47.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ICLR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15  Med: 9 Max: 50.1
Current: 47.5
-15
50.1

More Statistics

Revenue (TTM) (Mil) $1,698
EPS (TTM) $ 4.82
Beta0.44
Short Percentage of Float4.08%
52-Week Range $63.94 - 90.67
Shares Outstanding (Mil)53.78

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,732 1,817 1,960
EPS ($) 5.15 5.69 6.46
EPS without NRI ($) 5.15 5.69 6.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.38%
Dividends per Share ($)
» More Articles for ICLR

Headlines

Articles On GuruFocus.com
Scott Black’s Top 4 New Holdings of 3rd Quarter Nov 22 2016 
9 Companies Grantham Continues to Boost Nov 15 2016 
Dynamite Comes in Small Packages: 10 Small Caps to Get Explosive Returns Apr 01 2016 
ICON Selected by Genomics England to Support the Largest Genome Sequencing Project of Its Kind for C Feb 25 2016 
Probable Gainers Of A European Market Bounce Back Jan 25 2015 
Meridian Funds Comments on Icon PLC Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 

More From Other Websites
ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes May 24 2017
ETFs with exposure to ICON Plc : May 22, 2017 May 22 2017
Edited Transcript of ICLR earnings conference call or presentation 27-Apr-17 1:00pm GMT May 21 2017
ICON Named by Forbes as One of the Best Employers in America May 11 2017
Blog Coverage: Genomic Health Announces Favorable LCD on Medicare Coverage for Use of Oncotype DX... May 08 2017
ICON Plc :ICLR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 2, 2017 May 02 2017
ICON Plc – Value Analysis (NASDAQ:ICLR) : May 1, 2017 May 01 2017
ICON Plc breached its 50 day moving average in a Bullish Manner : ICLR-US : April 28, 2017 Apr 28 2017
Icon PLC beats 1Q profit forecasts Apr 27 2017
ICON Reports First Quarter 2017 Results Apr 27 2017
ICON Awarded Best CRO at World Vaccine Congress 2017 Apr 12 2017
Parexel Is Discovering the Drugs of the Future Apr 10 2017
Post Earnings Coverage as DexCom's Q4 Top-line Surged 31%; Outshined Forecasts Mar 16 2017
ICON Plc :ICLR-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Edited Transcript of ICLR earnings conference call or presentation 16-Feb-17 2:00pm GMT Feb 16 2017
Icon PLC meets 4Q profit forecasts Feb 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)